

NEOPROBE 1st QUARTER EARNINGS AND CLINICAL RESULTS CONFERENCE CALL
Conference Call Scheduled for 4:30 PM ET, Thursday, May 7th

DUBLIN, OHIO – April 30, 2009 -- Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced it would report its financial results for the first quarter of 2009 on Wednesday, May 6, 2009 after the close of the financial markets. In addition, Neoprobe announced that two investigators involved in the Company's Phase 3 clinical trial for Lymphoseek[®] for patients with breast cancer or melanoma are scheduled to present data related to their experience in the trial on May 7, 2009 at the Third International Symposium on Cancer Metastasis and the Lymphovascular System: Basis for Rational Therapy (May 6-9, 2009, San Francisco). The presentation by Dr. Anne Wallace of the Moores Cancer Center at the University of California, San Diego and Dr. Vernon Sondak of the H. Lee Moffitt Cancer Center and Research Institute is titled "Molecular targeting of Sentinel Nodes with Lymphoseek: Phase III Clinical Results for Breast Cancer and Melanoma." The Company intends to hold a conference call to discuss both the financial results for the first quarter of 2009 and the presentation of the clinical data following the May 7th clinical presentations. The Company has scheduled a conference call with the investment community for the afternoon of Thursday, May 7, 2009 at 4:30PM ET.

During the May 7th conference call, Neoprobe's President and CEO, David Bupp, and Vice President and CFO, Brent Larson, will provide a business update and discuss the Company's results for the first quarter of 2009. Neoprobe's Vice President, Pharmaceutical Research and Clinical Development, Frederick Cope, Ph.D., will participate in the call to discuss the results scheduled to be presented by the investigators at the symposium earlier in the day.

The conference call can be accessed as follows:

Conference Call Information			
TO PARTICIPATE LIVE:		TO LISTEN TO A REPLAY:	
Date:	May 7, 2009	Available until:	May 14, 2009
Time:	4:30 PM ET	Toll-free (U.S.) Dial in # :	877-660-6853
		International Dial in # :	201-612-7415
Toll-free (U.S.) Dial in # :	877-407-8033	Replay Passcodes:	
International Dial in # :	201-689-8033	Account #:	286
		Conference ID #:	321301

About Neoprobe

Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neo2000[®] line of gamma detection systems that are widely used by cancer surgeons and is commercializing the Quantix[®] line of blood flow measurement products developed by its subsidiary, Cardiosonix Ltd. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek[®] and RIGScan[®] CR. Neoprobe's subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe's strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.neoprobe.com